Roche (RHHBY) CEO Thomas Schinecker says that President Trump’s executive order seeking to tie U.S. drug prices to those abroad could impact future investment in America, The Wall Street Journal’s Jared S. Hopkins reports. The company has planned to invest $50B in the U.S. over the next five years, and when asked how the order, signed last month and opposed by the industry, could affect such plans, Schinecker said Roche would only say that the company was in discussions with the government. “These kinds of investments, you can only make if you can afford those investments. If you cut into that significantly, then the whole industry wouldn’t be able to invest these kinds of monies,” Schinecker said at the WSJ CEO Council.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- RFK Jr. names eight members to vaccine panel, WSJ reports
- RFK Jr. names new CDC vaccine advisory panel picks, STAT reports
- Trump Trade: RFK Jr. removes members of vaccine-advising CDC panel
- RFK Jr. reconstituting vaccine advisory committee, retiring 17 current members
- RFK Jr. removes members of vaccine-advising CDC panel, CNBC reports